Impact of Anxiety and Depression on Implicit and Explicit Memory Performance (ADEM)

October 29, 2024 updated by: Shaghayegh Radmehr, Islamic Azad University, Tehran

Cohort Study on the Differential Impact of Anxiety and Depression on Implicit and Explicit Memory Performance

This study examines the effect of anxiety and depression on memory processes, focusing on implicit and explicit memory. Implicit memory involves unconscious recall, such as recognizing familiar words without effort, while explicit memory requires conscious recollection of specific information. The study aims to investigate whether individuals with depression and anxiety show differences in these types of memory, which may contribute to biases related to their emotional states.

Participants were divided into three groups: individuals with depressive disorder, individuals with generalized anxiety disorder, and a control group with no emotional disorders. Each group was assessed using tasks designed to measure both implicit and explicit memory performance. The goal is to enhance understanding of memory biases in individuals with depression and anxiety, potentially supporting more targeted interventions.

Study Overview

Detailed Description

This cohort study is designed to explore potential memory biases in individuals with depressive and anxiety disorders compared to a control group. The study includes 27 participants divided into three groups: nine individuals diagnosed with major depressive disorder, nine with generalized anxiety disorder, and nine control subjects with no history of emotional disorders. All participants were matched by age and education level.

Participants completed standardized tasks and assessments, including the Spielberger State-Trait Anxiety Inventory and various memory tasks such as word decoding and recognition memory tasks. These tasks aim to evaluate mood-congruent biases in memory recall. Data collection will focus on analyzing any distinct memory processing patterns in depression and anxiety to improve psychological treatment approaches.

Study Type

Observational

Enrollment (Actual)

27

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tehran, Iran, Islamic Republic of, 14176
        • Tehran Institute of Psychiatry and/or Shahid Esmaili Clinic.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

A sample of individuals from Tehran Institute of Psychiatry and Shahid Esmaili Clinic, including patients with depressive disorder, generalized anxiety disorder, and a control group of healthy individuals with no history of emotional disorders.

Description

Inclusion Criteria:

  • Adults aged 18 years or older
  • Individuals diagnosed with major depressive disorder (Group 1)
  • Individuals diagnosed with generalized anxiety disorder (Group 2)
  • Healthy individuals with no history of emotional disorders (Group 3)

Exclusion Criteria:

  • History of neurological disorders
  • Visual impairments
  • Substance abuse or drug addiction
  • Psychiatric hospitalizations unrelated to primary diagnosis (for Groups 1 and 2)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1
Depressive Disorder group - 9 participants.
Group 2
Generalized Anxiety Disorder group - 9 participants.
Group 3
Control group - 9 participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Explicit Memory Bias
Time Frame: At a single time point during the experimental session, approximately 1 day
The primary outcome is to assess explicit memory bias by measuring word recognition in participants with depressive disorder, generalized anxiety disorder, and a control group. Word recognition accuracy and response times are evaluated to determine mood-congruent biases specific to each group.
At a single time point during the experimental session, approximately 1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implicit Memory Bias
Time Frame: At a single time point during the experimental session, approximately 1 hour
Secondary outcome is to assess implicit memory bias using a tachistoscopic word recognition task, measuring participants' ability to identify emotionally congruent words (e.g., words associated with depression, anxiety, and neutral words) without conscious awareness.
At a single time point during the experimental session, approximately 1 hour

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mood Congruence in Recognition Performance
Time Frame: At a single time point during the experimental session, approximately 1 hour
Analysis of mood-congruent recognition performance across different emotional word types (depression-related, anxiety-related, pleasant, and neutral) to determine if participants show selective attention based on mood.
At a single time point during the experimental session, approximately 1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 10, 2024

Primary Completion (Actual)

August 30, 2024

Study Completion (Actual)

September 30, 2024

Study Registration Dates

First Submitted

October 25, 2024

First Submitted That Met QC Criteria

October 27, 2024

First Posted (Actual)

October 29, 2024

Study Record Updates

Last Update Posted (Actual)

October 31, 2024

Last Update Submitted That Met QC Criteria

October 29, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder (MDD)

Subscribe